ArticleInfection and immunity1995
Protection of gerbils from amebic liver abscess by immunization with recombinant Entamoeba histolytica 29-kilodalton antigen.
Article in Infection and immunity, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 55 citations in OpenAlex.
- A Novel TLR4-Binding Domain of Peroxiredoxin FromFrontiers in immunology · 2021Article
- Entamoeba histolytica: Host parasite interactions at the colonic epithelium.Tissue barriers · 2017Article
- Immunization with the Entamoeba histolytica surface metalloprotease EhMSP-1 protects hamsters from amebic liver abscess.Infection and immunity · 2015Article
- DNA-protein immunization using Leishmania peroxidoxin-1 induces a strong CD4+ T cell response and partially protects mice from cutaneous leishmaniasis: role of fusion murine granulocyte-macrophage colony-stimulating factor DNA adjuvant.PLoS neglected tropical diseases · 2014Article
- Expression, purification, and evaluation of recombinant LecA as a candidate for an amebic colitis vaccine.Vaccine · 2014Article
- Peroxynitrite and peroxiredoxin in the pathogenesis of experimental amebic liver abscess.BioMed research international · 2014Review
- The future for vaccine development against Entamoeba histolytica.Human vaccines & immunotherapeutics · 2014Review
- Peroxiredoxins in parasites.Antioxidants & redox signaling · 2012Review
- Seroprevalence of Entamoeba histolytica infection in China.The American journal of tropical medicine and hygiene · 2012Article
- Progress in the research on diagnosis and vaccines in amebiasis.Tropical parasitology · 2011Article
- Protection against intestinal amebiasis by a recombinant vaccine is transferable by T cells and mediated by gamma interferon.Infection and immunity · 2009Article
- The 29-kilodalton thiol-dependent peroxidase of Entamoeba histolytica is a factor involved in pathogenesis and survival of the parasite during oxidative stress.Eukaryotic cell · 2007Article
- Evaluation of recombinant fragments of Entamoeba histolytica Gal/GalNAc lectin intermediate subunit for serodiagnosis of amebiasis.Journal of clinical microbiology · 2004Article
- Schistosome infection stimulates host CD4(+) T helper cell and B-cell responses against a novel egg antigen, thioredoxin peroxidase.Infection and immunity · 2001Article
- Protection of gerbils from amebic liver abscess by vaccination with a 25-mer peptide derived from the cysteine-rich region of Entamoeba histolytica galactose-specific adherence lectin.Infection and immunity · 2000Article
- Cysteine proteinases and the pathogenesis of amebiasis.Clinical microbiology reviews · 2000Review
- Experimental infection of Mongolian gerbils with wild-type and mutant Helicobacter pylori strains.Infection and immunity · 1998Article
- Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family.Infection and immunity · 1998Article
- Protection against invasive amebiasis by a single monoclonal antibody directed against a lipophosphoglycan antigen localized on the surface of Entamoeba histolytica.The Journal of experimental medicine · 1997Article
- Progress towards development of a vaccine for amebiasis.Clinical microbiology reviews · 1997Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
The goal of our study was to obtain a highly conserved Entamoeba histolytica recombinant antigen for study as a subunit amebiasis vaccine. We screened a Uni-Zap cDNA library of E. histolytica (strain HM1:IMSS) with human immune sera and isolated a dominant 804-bp cDNA clone. A 33-kDa fusion protein expressed from the cDNA clone was determined by monoclonal antibody binding, DNA hybridization, and nucleotide sequence to be the complete E. histolytica 29-kDa antigen. Serum antibodies to the recombinant protein were detected by enzyme-linked immunosorbent assay in 80% of subjects from Egypt and South Africa with amebic liver abscess. Similar results were found with the native 29-kDa protein. Native and recombinant 29-kDa antigens induced proliferation of lymphocytes harvested from patients with amebic liver abscess (P < 0.01 compared with controls). Intraperitoneal immunization of gerbils with the recombinant fusion protein (10 micrograms) with Titermax adjuvant elicited an antigen-specific serum immunoglobulin G antibody response and was partially protective (54%) against intrahepatic challenge with 5 x 10(5) virulent axenic trophozoites (strain HM1:IMSS). In summary, the recombinant form of the E. histolytica 29-kDa antigen demonstrated serologic specificity for amebic liver abscess, exhibited conserved T-cell epitopes, and was effective as a subunit vaccine in an experimental animal model of amebic liver abscess.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.